| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.10B | 10.96B | 10.92B | 10.90B | 10.53B | 11.88B |
| Gross Profit | 6.00B | 5.96B | 5.78B | 5.93B | 6.08B | 6.73B |
| EBITDA | 1.53B | 1.44B | 1.47B | 84.16M | 1.12B | 1.36B |
| Net Income | 663.90M | 878.44M | 591.63M | -628.79M | 510.09M | 715.41M |
Balance Sheet | ||||||
| Total Assets | 10.98B | 11.32B | 11.42B | 10.87B | 11.44B | 8.87B |
| Cash, Cash Equivalents and Short-Term Investments | 5.04B | 5.75B | 4.92B | 4.36B | 3.61B | 3.62B |
| Total Debt | 600.00M | 857.45M | 1.19B | 1.48B | 1.57B | 209.15M |
| Total Liabilities | 8.61B | 8.52B | 9.03B | 9.06B | 8.75B | 5.92B |
| Stockholders Equity | 2.37B | 2.80B | 2.39B | 1.81B | 2.69B | 2.93B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 1.37B | 901.23M | 1.38B | -708.88M | 338.84M |
| Operating Cash Flow | 0.00 | 1.46B | 1.21B | 1.78B | -213.40M | 669.08M |
| Investing Cash Flow | 0.00 | 236.62M | -292.00M | -325.63M | -510.15M | -278.35M |
| Financing Cash Flow | 0.00 | -859.23M | -361.39M | -702.63M | 712.28M | -392.52M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ¥49.71B | 28.22 | ― | 0.52% | 26.98% | 19.69% | |
65 Neutral | ¥10.84B | 12.15 | ― | 2.16% | 2.75% | 25.24% | |
64 Neutral | ¥613.64B | 27.38 | 19.76% | 1.47% | 11.81% | 16.69% | |
61 Neutral | ¥17.95B | 90.38 | ― | 2.31% | 9.71% | -70.49% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
61 Neutral | ¥16.36B | -46.59 | ― | ― | ― | ― | |
52 Neutral | ¥120.74B | 162.31 | ― | 0.14% | 36.42% | 28.23% |
GMO Pepabo reported flat net sales of ¥10.96 billion for the year ended 31 December 2025, but sharply higher profitability, with operating profit up 12.5% to ¥932 million and profit attributable to owners of parent surging 48.5% to ¥878 million. The company strengthened its financial base, lifting its equity ratio to 24.7%, growing year-end cash and cash equivalents to ¥5.75 billion, and more than doubling the annual dividend to ¥111 per share, including a special payout.
The group also recorded higher net assets, reflecting improved earnings and capital efficiency, while reshaping its consolidation scope by adding CN Inc. and excluding GMO Creators Network, Inc. For 2026, Pepabo forecasts modest sales growth to ¥11.0 billion and a further rise in operating profit to ¥1.05 billion, but projects lower ordinary profit and net income as profitability normalizes after the strong 2025 results.
The most recent analyst rating on (JP:3633) stock is a Buy with a Yen2442.00 price target. To see the full list of analyst forecasts on GMO Pepabo, Inc. stock, see the JP:3633 Stock Forecast page.